nach oben

Journal of Mammary Gland Biology and Neoplasia

Erschienen in:

01.06.2009

The Role of Cathepsins in Involution and Breast Cancer

verfasst von: Christine J. Watson, Peter A. Kreuzaler

Erschienen in: Journal of Mammary Gland Biology and Neoplasia | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Cysteine cathepsins are proteolytic enzymes that reside in endolysosomal vesicles. Some are expressed constitutively while others are transcriptionally regulated. However, the expression and subcellular localization of cathepsins changes during cancer progression and cathepsins have been shown to be causally involved in various aspects of tumorigenesis including metastasis. The use of mouse models of breast cancer genetically ablated for cathepsin B has shown that both the growth of the primary tumor and the extend of lung metastasis is reduced by the loss of cathepsin B. The role of cathepsins in involution of the mammary gland has received little attention although it is clear that cathepsins are involved in tissue remodeling in the second phase of involution. We discuss here the roles of cathepsins and their endogenous inhibitors in breast tumorigenesis and post-lactational involution.

Watson CJ. Involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ. Breast Cancer Res. 2006;8(2):203.PubMedCrossRef

Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, et al. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA. 1997;94:3425–30.PubMedCrossRef

Noble MS, Hurley WL. Effects of secretion removal on bovine mammary gland function following an extended milk stasis. J Dairy Sci. 1999;82:1723–30.PubMedCrossRef

Lund LR, Rømer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development. 1996;122:181–93.PubMed

Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999;13:2604–16.PubMedCrossRef

Humphreys RC, Bierie B, Zhao L, Raz R, Levy D, Hennighausen L. Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology. 2002;143:3641–50.PubMedCrossRef

Bresden DE. Toward a mechanistic taxonomy for cell death programs. Stroke. 2007;38:652–65.CrossRef

Henriquez M, Armisén R, Stutzin A, Quest AF. Cell death by necrosis, a regulated way to go. Curr Mol Med. 2008;8(3):187–206.PubMedCrossRef

Golstein P, Kroemer G. Redundant cell death mechanisms as relics and backups. Cell Death Differ. 2005;12(Suppl 2):1490–6.PubMedCrossRef

10.

Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008;9(12):1004–10.PubMedCrossRef

11.

Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 2008;135(7):1311–23.PubMedCrossRef

12.

Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112–9.PubMedCrossRef

13.

Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27(50):6434–51.PubMedCrossRef

14.

Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol. 2001;3(11):E255–63.PubMedCrossRef

15.

Schütze S, Machleidt T, Adam D, Schwandner R, Wiegmann K, Kruse ML, et al. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem. 1999;274(15):10203–12.PubMedCrossRef

16.

Kågedal K, Zhao M, Svensson I, Brunk UT. Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem J. 2001;359(Pt 2):335–43.PubMedCrossRef

17.

Werneburg NW, Guicciardi ME, Bronk SF, Gores GJ. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol. 2002;283(4):G947–56.PubMed

18.

Fehrenbacher N, Bastholm L, Kirkegaard-Sørensen T, Rafn B, Bøttzauw T, Nielsen C, et al. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res. 2008;68(16):6623–33.PubMedCrossRef

19.

Bidère N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C, et al. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J Biol Chem. 2003;278(33):31401–11.PubMedCrossRef

20.

Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem. 2007;282(39):28960–70.PubMedCrossRef

21.

Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–90.PubMedCrossRef

22.

Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem. 2001;276(5):3149–57.PubMedCrossRef

23.

Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. Bioessays. 2005;27(9):894–903.PubMedCrossRef

24.

Hojilla CV, Wood GA, Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 2008;210(2):205.CrossRef

25.

Almholt K, Green KA, Juncker-Jensen A, Nielsen BS, Lund LR, Rømer J. Extracellular proteolysis in transgenic mouse models of breast cancer. J Mammary Gland Biol Neoplasia. 2007;12(1):83–97.PubMedCrossRef

26.

Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917–29.PubMedCrossRef

27.

Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta. 2000;1477(1–2):98–111.PubMed

28.

Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001;20(17):4629–33.PubMedCrossRef

29.

Turk V, Turk B, Guncar G, Turk D, Kos J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul. 2002;42:285–303.PubMedCrossRef

30.

de Duve C. Lysosomes revisited. Eur J Biochem. 1983;137(3):391–7.PubMedCrossRef

31.

Saftig P, Hunziker E, Everts V, Jones S, Boyde A, Wehmeyer O, et al. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv Exp Med Biol. 2000;477:293–303.PubMedCrossRef

32.

Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 1999;10(2):197–206.PubMedCrossRef

33.

Lagadic-Gossmann D, Huc L, Lecureur V. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ. 2004;11(9):953–61.PubMedCrossRef

34.

Turk B, Bieth JG, Björk I, Dolenc I, Turk D, Cimerman N, et al. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol Chem Hoppe Seyler. 1995;376(4):225–30.PubMed

35.

Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol. 2007;8(8):622–32.PubMedCrossRef

36.

Cirman T, Oresic K, Droga Mazovec G, Turk V, Reed JC, Myers RM, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by Cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem. 2004;279:3578–87.PubMedCrossRef

37.

Blomgran R, Zheng L, Stendahl O. Cathepsin-cleaved Bid promotes apoptosis in human neutrophils via oxidative stress-induced lysosomal membrane permeabilization. J Leukoc Biol. 2007;81(5):1213–23.PubMedCrossRef

38.

Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem. 2008;283:19140–50.PubMedCrossRef

39.

Reiners JJ Jr, Caruso JA, Mathieu P, Chelladurai B, Yin XM, Kessel D. Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves Bid cleavage. Cell Death Differ. 2002;9(9):934–44.PubMedCrossRef

40.

Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20(5):543–56.PubMedCrossRef

41.

Yasothornsrikul S, Greenbaum D, Medzihradszky KF, Toneff T, Bundey R, Miller R, et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A. 2003;100(16):9590–5.PubMedCrossRef

42.

Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell. 2004;14(2):207–19.PubMedCrossRef

43.

Koblinski JE, Dosescu J, Sameni M, Moin K, Clark K, Sloane BF. Interaction of human breast fibroblasts with collagen I increases secretion of procathepsin B. J Biol Chem. 2002;277(35):32220–7.PubMedCrossRef

44.

Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, Ziegler G. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci. 1994 Feb;107(Pt 2):373--84.PubMed

45.

Roshy S, Sameni M, Koblinski J, Sloane BF. Cathepsin B in the development of mammary acini in vitro. Toxicol Pathol. 2004;32:159.CrossRef

46.

Cavallo-Medved D, Rudy D, Blum G, Bogyo M, Caglic D, Sloane BF. Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res. 2009;315(7):1234–46.PubMedCrossRef

47.

Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, et al. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol. 2009;174(4):1172–90.PubMedCrossRef

48.

Piwnica D, Fernandez I, Binart N, Touraine P, Kelly PA, Goffin V. A new mechanism for prolactin processing into 16K PRL by secreted cathepsin D. Mol Endocrinol. 2006;20(12):3263–78.PubMedCrossRef

49.

Castino R, Delpal S, Bouguyon E, Demoz M, Isidoro C, Ollivier-Bousquet M. Prolactin promotes the secretion of active cathepsin D at the basal side of rat mammary acini. Endocrinology. 2008;149(8):4095–105.PubMedCrossRef

50.

Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor actator of nuclear factor-kappaB ligand. Cancer Res. 2008;68(14):5803–11.PubMedCrossRef

51.

Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 2004;6(2):R92–109.PubMedCrossRef

52.

Han J, Luo T, Gu Y, Li G, Jia W, Luo M. Cathepsin K regulates adipocyte differentiation: possible involvement of type I collagen degradation. Endocr J. 2009;56(1):55–63.PubMedCrossRef

53.

Burke MA, Hutter D, Reshamwala RP, Knepper JE. Cathepsin L plays an active role in involution of the mouse mammary gland. Dev Dyn. 2003;227(3):315–22.PubMedCrossRef

54.

Guenette RS, Mooibroek M, Wong K, Wong P, Tenniswood M. Cathepsin B, a cysteine protease implicated in metastatic progression, is also expressed during regression of the rat prostate and mammary glands. Eur J Biochem. 1994;226(2):311–21.PubMedCrossRef

55.

Zaragozá R, Torres L, García C, Eroles P, Corrales F, Bosch A, et al. Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation. Biochem J. 2009;419(2):279–88.PubMedCrossRef

56.

Zaragozá R, Miralles VJ, Rus AD, García C, Carmena R, García-Trevijano ER, et al. Weaning induces NOS-2 expression through NF-kappaB modulation in the lactating mammary gland: importance of GSH. Biochem J. 2005;391(Pt 3):581–8.PubMed

57.

Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6(10):764–75.PubMedCrossRef

58.

Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20(5):543–56.PubMedCrossRef

59.

Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. 1992;282(Pt 1):273–8.PubMed

60.

Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994;54(24):6517–25.PubMed

61.

Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006;66(10):5242–50.PubMedCrossRef

62.

Frosch BA, Berquin I, Emmert-Buck MR, Moin K, Sloane BF. (1999) Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS. 1999;107(1):28–37.PubMedCrossRef

63.

64.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.PubMedCrossRef

65.

Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A. 2002;99(12):7883–8.PubMedCrossRef

66.

Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Krüger A. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene. 2008;27(30):4191–9.PubMedCrossRef

67.

Schurigt U, Sevenich L, Vannier C, Gajda M, Schwinde A, Werner F, et al. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem. 2008 Aug;389(8):1067–74.PubMedCrossRef

68.

Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991;285:213–9.PubMedCrossRef

69.

Colbert JD, Plechanovová A, Watts C. Glycosylation directs targeting and activation of cystatin f from intracellular and extracellular sources. Traffic. 2009;10(4):425–37.PubMedCrossRef

70.

Lah TT, Kokalj-Kunovar M, Strukelj B, Pungercar J, Barlic-Maganja D, Drobnic-Kosorok M, et al. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer. 1992;50(1):36–44.PubMedCrossRef

71.

Parker BS, Ciocca DR, Bidwell BN, Gago FE, Fanelli MA, George J, et al. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol. 2008;214(3):337–46.PubMedCrossRef

72.

Zhang J, Shridhar R, Dai Q, Song J, Barlow SC, Yin L, et al. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res. 2004;64(19):6957–64.PubMedCrossRef

73.

Vigneswaran N, Wu J, Muller S, Zacharias W, Narendran S, Middleton L. Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells—a preliminary study. Pathol Res Pract. 2005;200(11–12):753–62.PubMedCrossRef

74.

Ai L, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD, et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 2006;66(16):7899–909.PubMedCrossRef

75.

Dbaibo GS, Hannun YA. Cytokine response modifier A (CrmA): a strategically deployed viral weapon. Clin Immunol Immunopathol. 1998;86(2):134–40.PubMedCrossRef

76.

Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S, et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol. 1998;18(11):6387–98.PubMed

77.

Khalkhali-Ellis Z, Hendrix MJ. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res. 2007;67(8):3535–9.PubMedCrossRef

78.

Zhang M, Magit D, Botteri F, Shi HY, He K, Li M, et al. Maspin plays an important role in mammary gland development. Dev Biol. 1999;215(2):278–8.PubMedCrossRef

79.

Zhang M, Shi Y, Magit D, Furth PA, Sager R. Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene. 2000;19(52):6053–8.PubMedCrossRef

80.

Zhang M. Multiple functions of maspin in tumor progression and mouse development. Front Biosci. 2004;9:2218–26.PubMedCrossRef

Titel: The Role of Cathepsins in Involution and Breast Cancer
verfasst von: Christine J. Watson
Peter A. Kreuzaler
Publikationsdatum: 01.06.2009
Verlag: Springer US
Erschienen in: Journal of Mammary Gland Biology and Neoplasia / Ausgabe 2/2009
Print ISSN: 1083-3021
Elektronische ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-009-9126-8

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

The Role of Cathepsins in Involution and Breast Cancer

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Differentiation of the Mammary Epithelial Cell during Involution: Implications for Breast Cancer

Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer

Pregnancy and Breast Cancer: when They Collide

Macrophages in Breast Cancer: Do Involution Macrophages Account for the Poor Prognosis of Pregnancy-Associated Breast Cancer?

Mammary Involution and Breast Cancer Risk: Transgenic Models and Clinical Studies

A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie